Details for New Drug Application (NDA): 062032
✉ Email this page to a colleague
NDA 062032 describes ERYPAR, which is a drug marketed by Parke Davis and Warner Chilcott and is included in two NDAs. Additional details are available on the ERYPAR profile page.
The generic ingredient in ERYPAR is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
The generic ingredient in ERYPAR is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
Summary for 062032
| Tradename: | ERYPAR |
| Applicant: | Parke Davis |
| Ingredient: | erythromycin stearate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 250MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | EQ 500MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
